Radcliffe Capital Management’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Radcliffe Capital Management’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-165,205	Closed	-$1.7M	–	563
2023 Q2	$1.7M	Hold	165,205	–	–	0.14%	193
2023 Q1	$1.67M	Hold	165,205	–	–	0.1%	246
2022 Q4	$1.65M	Hold	165,205	–	–	0.05%	533
2022 Q3	$1.61M	Hold	165,205	–	–	0.04%	742
2022 Q2	$1.6M	Buy	165,205 +19,082	+13%	+$186K	0.04%	781
2022 Q1	$1.42M	Buy	+146,123	New	+$1.41M	0.03%	817

Radcliffe Capital Management's DALS Position: Q3 2023 in Review

Radcliffe Capital Management sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 165,205 shares — an estimated $1.7M sold.

Radcliffe Capital Management first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $1.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

Radcliffe Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Radcliffe Capital Management sold 165,205 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $1.7M.
Radcliffe Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q1 2022 and held it in 6 quarters.
Radcliffe Capital Management's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $1.7M in Q2 2023.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.